Researchers suggest ECM-binding mAbs could improve safety, efficacy in cancer

A Science Translational Medicine study suggests engineering extracellular matrix (ECM)-binding antibodies for checkpoint blockade could delay tumor growth and reduce immunotherapy-related adverse events in cancer by localizing therapy and

Read the full 291 word article

User Sign In